Adecto Pharmaceuticals is a pre-clinical stage company, developing the first antibody-based targeted treatment against aggressive ADAM8-positive cancers and a companion diagnostic to identify patients who can benefit from it. If you are interested in becoming an investor in Adecto Pharmaceuticals or in exploring the possibility of a partnership, please do not hesitate to contact us.